KURN 📈 Kuros Biosciences - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0325814116
KURN: Bone Grafts, Pharmaceuticals, Medical Devices
Kuros Biosciences AG is a biopharmaceutical company that focuses on developing and commercializing innovative solutions for tissue repair and bone regeneration. The company operates globally, with a presence in the United States, the European Union, and other international markets.
The company's business is divided into three main segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The Medical Devices segment is responsible for the development and commercialization of advanced bone grafts, including MagnetOs Granules, MagnetOs Putty, MagnetOs Easypack Putty, and Magnetos Flex Matrix. These products utilize the company's proprietary NeedleGrip surface technology, which provides a unique submicron needle-shaped surface that enhances bone growth and regeneration.
In the Pharmaceuticals segment, Kuros Biosciences AG is developing a pipeline of Fibrin-PTH products, including KUR-111 and KUR-113, which are currently in Phase 2b clinical trials for trauma indications. Additionally, KUR-113 is in a Phase 2a clinical trial for spinal indications. These products have the potential to revolutionize the treatment of bone-related disorders and injuries.
Founded in 2016, Kuros Biosciences AG is headquartered in Schlieren, Switzerland, and is committed to improving patient outcomes through innovative and effective solutions. For more information, please visit the company's website at https://www.kuros.ch.
Additional Sources for KURN Stock
KURN Stock Overview
| Market Cap in USD | 1,064m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Industry | Health Care Equipment & Supplies |
| TER | 0.00% |
| IPO / Inception |
KURN Stock Ratings
| Growth 5y | 73.5% |
| Fundamental | -46.3% |
| Dividend | - |
| Rel. Performance Sector | 127 |
| Analysts | - |
| Fair Price Momentum | 21.84 CHF |
| Fair Price DCF | - |
KURN Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 0.00% |
KURN Growth Ratios
| Growth Correlation 3m | 56.4% |
| Growth Correlation 12m | 98% |
| Growth Correlation 5y | 26% |
| CAGR 5y | 54.96% |
| CAGR/Mean DD 5y | 2.10 |
| Sharpe Ratio 12m | 1.99 |
| Alpha | 258.14 |
| Beta | 0.60 |
| Volatility | 72.43% |
| Current Volume | 211.6k |
| Average Volume 20d | 498.6k |
As of December 06, 2024, the stock is trading at CHF 19.78 with a total of 211,605 shares traded.
Over the past week, the price has changed by -10.90%, over one month by -29.10%, over three months by +17.46% and over the past year by +297.99%.
Probably not. Based on ValueRay Fundamental Analyses, Kuros Biosciences (SW:KURN) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -46.26 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KURN as of December 2024 is 21.84. This means that KURN is currently undervalued and has a potential upside of +10.41% (Margin of Safety).
Kuros Biosciences has no consensus analysts rating.
According to ValueRays Forecast Model, KURN Kuros Biosciences will be worth about 24 in December 2025. The stock is currently trading at 19.78. This means that the stock has a potential upside of +21.23%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 20.1 | 1.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24 | 21.2% |